These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8630283)

  • 21. ProGRP: a new biomarker for small cell lung cancer.
    Molina R; Filella X; Augé JM
    Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
    Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
    Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
    Miyake Y; Kodama T; Yamaguchi K
    Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.
    Han K; Chen Y; Sun X; Wen L; Wu Y; Chen S; Wei L; Yu J; Zeng T; Jiang L; Tan L
    Clin Transl Oncol; 2024 Oct; ():. PubMed ID: 39397200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
    WANG J; GAO J; HE J
    Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
    Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
    Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors.
    Honda Y; Katagiri H; Takahashi M; Murata H; Wasa J; Hosaka S; Ishida Y; Ito I; Muramatsu K; Mochizuki T; Matsuyama Y; Yamaguchi K
    Int J Clin Oncol; 2019 Nov; 24(11):1468-1478. PubMed ID: 31264078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels.
    Goto K; Kodama T; Hojo F; Kubota K; Kakinuma R; Matsumoto T; Ohmatsu H; Sekine I; Nagai K; Nishiwaki Y
    Cancer; 1998 Mar; 82(6):1056-61. PubMed ID: 9506349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.
    Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N
    Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
    Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
    Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.
    Lyubimova NV; Kuz'minov AE; Markovich AA; Lebedeva AV; Timofeev YS; Stilidi IS; Kushlinskii NE
    Bull Exp Biol Med; 2022 Jun; 173(2):257-260. PubMed ID: 35737164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
    Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
    Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Automated time-resolved immunofluorometric assay for progastrin-releasing peptide.
    Nordlund MS; Warren DJ; Nustad K; Bjerner J; Paus E
    Clin Chem; 2008 May; 54(5):919-22. PubMed ID: 18443179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
    Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
    Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.
    Scagliotti GV; Piani M; Gatti E; Gozzelino F; Albera C; Pozzi E
    Eur Respir J; 1989 Sep; 2(8):746-50. PubMed ID: 2553476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.